Blog dermatologico
2017
Dermatite atopica. Un problema anche per l'adulto e con incidenza in aumento
Rassegna stampaQuesta patologia colpisce oggi il 2-5% della popolazione. Nelle sue forme più gravi il costante prurito e le manifestazioni dei sintomi sulla pelle portano a ripercussioni psicologiche forti per i pazienti. Sanofi e Regeneron Pharmace...
Leggi tutto2017
Spray Replaces Lost Skin Bacteria, Improves Keratosis Pilaris
Rassegna stampaA treatment that replaces natural-biome bacteria with ammonia-oxidising bacteria appears to improve the cosmetic appearance and texture of keratosis pilaris, according to results of a small phase 2 study reported at the 2017 Annual Mee...
Leggi tutto2017
Patients With Immunosuppressive Diseases/Treatments Experience Greater Complications After Mohs Surgery
Rassegna stampaThe risk of a patient having a complication following Mohs Micrographic Surgery increases if that patient has a history of immunosuppressive diseases or treatments, according to results of a 4-year retrospective, chart review presented...
Leggi tutto2017
Topical Oxymetazoline 1.0% Shows Long-Term Efficacy for Persistent Facial Erythema Associated With Rosacea
Rassegna stampaPatients were able to tolerate treatment of their rosacea with topical 1% oxymetazoline hydrochloride gel for 1 year with acceptable reduction of redness and few adverse events, according to a study presented here at the 75th Annual Me...
Leggi tutto2017
Ixekizumab Superior to Ustekinumab for Treating Psoriasis
Rassegna stampaPatients with psoriasis treated with the targeted agent ixekizumab appear to have better outcomes at 24 weeks than those treated with ustekinumab, according to the 24-week data of the ongoing IXORA-S trial presented at the 2017 Annual ...
Leggi tutto2017
Patients Aged Older Than 85 Years Who Have Mohs Surgery Average 6 More Years of Life
Rassegna stampaPatients aged older than 85 years can safely undergo Mohs micrographic surgery to remove non-melanoma skin cancer and still have years of good quality of life, researchers reported here at the 75th Annual Meeting of the American Academ...
Leggi tutto2017
Psoriasi, la terapia non è sufficiente per un malato su cinque
Rassegna stampaUn quinto dei pazienti seguiti con la cosiddetta «terapia sistemica» continua ad avere problemi significativi. Non bastano solo i farmaci, serve anche la pratica di stili di vita corretti: fumo e sovrappeso peggiorano le lesioni...
Leggi tutto2017
Psoriasi, con la depressione sale il rischio di sviluppare artrite psoriasica?
Rassegna stampaPsoriasi e depressione, un'accoppiata nota da tempo ma da tenere sotto controllo....
Leggi tutto2017
Psoriasi. Niente vita di coppia per il 75% dei pazienti
Rassegna stampaIl 90% dei soggetti con psoriasi genitale dichiara effetti negativi sull’umore, il 75% dice addio alla propria vita sessuale e il 55% riporta una riduzione del desiderio sessuale a causa della malattia. Questi i dati presentati allâ€...
Leggi tutto2017
Psoriasi. Presentati al meeting annuale dell'American Academy of Dermatology i risultati di ixekizumab
Rassegna stampaArrivano dall'Annual Meeting dell'American Academy of Dermatology in corso a Orlando i dati sull'efficacia a lungo termine di ixekizumab di Eli Lilly per la cura della psoriasi in forma da moderata a grave....
Leggi tutto2017
Delibera del CD relativa ai patrocini SIDeMaST
Comunicazioni ai sociIl Consiglio direttivo in data 26 gennaio 2017 ha deliberato che il patrocinio SIDeMaST venga concesso a tutte le iniziative in cui la Direzione Scientifica sia di un socio SIDeMaST e per le quali il CD abbia approvato il programma sci...
Leggi tutto2017
World directory of Psoriasis medical resources for patients
NewsSince 2013, the Psoriasis International Network (PIN) is listing services provided to psoriasis patients in dermatology centres worldwide and building an interactive directory...
Leggi tutto2017
La psoriasi può causare perdita dei capelli?
Rassegna stampaIl cuoio capelluto è una delle sedi più frequentemente colpite e spesso rappresenta la sede di esordio della malattia che, inizialmente, può essere identificata dal paziente come «forfora» particolarmente persistente....
Leggi tutto2017
Absent Tumour-Suppressors Allow Melanoma to Thwart Immunotherapy
Rassegna stampaIt's what's missing in the tumour genome -- not what's mutated -- that thwarts treatment of metastatic melanoma with immune checkpoint blockade drugs, according to a study published in the journal Science Translational Medicine...
Leggi tutto2017
Risk of Subsequent Malignancies Reduced Among Childhood Cancer Survivors
Rassegna stampaAlthough the risk of subsequent malignancies for survivors of childhood cancer diagnosed in the 1990s remains increased, the risk is lower compared with those diagnosed in the 1970s -- a decrease that is associated with a reduction in ...
Leggi tutto2017
Gut Bacteria Associated With Cancer Immunotherapy Response in Melanoma
Rassegna stampaPatients with melanoma patients' response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, according to a study presented at the 1st...
Leggi tutto2017
Depression Puts Patients With Psoriasis at Significantly Greater Risk of Psoriatic Arthritis
Rassegna stampaPatients with psoriasis who developed depression were at a 37% greater risk of subsequently developing psoriatic arthritis, compared with patients with psoriasis who did not develop depression, according to a study published in the Jou...
Leggi tutto2017
Link Between Initial Autoimmune Disorder and Later Autoimmune Disorders
Rassegna stampaPatients who develop an immune-mediated inflammatory disease (IMID) have a significantly increased risk of developing a subsequent IMID...
Leggi tutto2017
Daptomycin Effective Against Drug-Resistant Bacteria in Paediatric Skin Infections
Rassegna stampaDaptomycin, part of a new class of antibiotics currently approved only for use in adults, is effective and well-tolerated in children with Methicillin-resistant Staphylococcus aureus (MRSA), according to a study published in the March ...
Leggi tutto2017
FDA Approves Brodalumab to Treat Psoriasis
Rassegna stampaThe US Food and Drug Administration (FDA) has approved brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab is administered as an injection....
Leggi tutto